ArticleJournal of veterinary internal medicine
Hyperfibrinolysis in Cats: A Retrospective Case-Control Study of 154 Cats.
Article in Journal of veterinary internal medicine. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Hyperfibrinolysis in Cats: A Retrospective Case-Control Study of 154 Cats.Journal of veterinary internal medicineArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundHyperfibrinolysis (HFL) has not been well described in cats. HYPOTHESIS/
objectivesIdentify risk factors associated with HFL in cats and evaluate its association with survival. Our hypotheses were that cats share similar conditions as dogs and humans with HFL and that it is associated with a worse prognosis. ANIMALS: A total of 154 client-owned cats had thromboelastography (TEG) performed because of a variety of clinical conditions.
methodsRetrospective case-control study. Cases were defined as cats with HFL (clot lysis at 30 min [LY30] ≥ 5% or clot lysis at 60 min [LY60] ≥ 10% or both) and controls were cats that had TEG performed but without HFL. Signalment, conditions that may alter fibrinolysis, TEG variables, indications to perform TEG, and outcome were recorded.
resultsFifty-two cats (33.8%) with HFL and 102 controls (66.2%) were included. Demographic variables were similar between groups. Both liver disease (odds ratio [OR], 5.0; 95% confidence interval [CI], 2.4-10.6; p < 0.001) and the presence of cavitary effusion (OR, 5.9; 95% CI, 2.8-12.4; p < 0.001) were important risk factors for HFL. Cats with heart disease were less likely to have HFL (OR, 0.2; 95% CI, 0.1-0.5; p < 0.001). The presence of HFL was not associated with worse outcome (p = 0.84). Cats with HFL more often were hypocoagulable, whereas cats without HFL more often were hypercoagulable (p < 0.001). CONCLUSIONS AND CLINICAL IMPORTANCE: Liver disease and cavitary effusion are risk factors for HFL in cats. The presence of HFL did not affect survival.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.